Back to today’s briefing

Story perspectives

NHS Approves Groundbreaking Gene Therapy for Sickle Cell Disease

2/4/2025

31 4

Summary

NHS Approves Exa-Cel

The NHS has greenlit exagamglogene autotemcel (exa-cel), a revolutionary gene-editing therapy for sickle cell disease, igniting hope for a cure. Utilizing cutting-edge CRISPR technology, this one-time treatment modifies patients' stem cells, aiming to eradicate painful crises. For eligible patients aged 12 and up, exa-cel promises to change lives, especially for those lacking suitable donors.

Summary

Government Funds Gene Therapy

The federal government is launching a groundbreaking program to assist states in funding gene therapies for sickle cell disease, like exa-cel. This model promises value for taxpayers, offering refunds for ineffective treatments. Connecticut's DSS remains hopeful about overcoming hurdles to provide this life-changing therapy, with aspirations for wider use down the line.

1 of 2

NHS Approves Exa-Cel

The NHS has greenlit exagamglogene autotemcel (exa-cel), a revolutionary gene-editing therapy for sickle cell disease, igniting hope for a cure. Utilizing cutting-edge CRISPR technology, this one-time treatment modifies patients' stem cells, aiming to eradicate painful crises. For eligible patients aged 12 and up, exa-cel promises to change lives, especially for those lacking suitable donors.

1 / 2